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We showed previously that expressing tumor-associated antigens (TAA) from 
Vesicular Stomatitis Virus eradicates established tumors. We show here that 
truncation of TAA expressed from VSV can occur to preserve the ability of the virus 
to replicate efficiently. We observed that truncation of VSV-expressed TAA affects 
the processing of the antigen, causing a bias towards an IL-17 anti-tumor response 
which was raised by cumulative signaling from different types of APC, each 
presenting specific, truncated antigens.  Whereas processing of full length, self-TAA  
invoked an IFN-ぐ based, CD8+ dependent response, truncated versions of the same 
self-TAA (likely to be poorly and incompletely folded) were processed through a 
class II-dependent pathway, and invoked an IL-17 based response. Significantly, the 
IL-17-mediated anti tumor response was both more therapeutic, and durable, than 
the response against full length self-TAA.  These data show that the type/potency of 
anti-tumor immune responses against self-TAA can be manipulated in vivo through 
the nature of the self protein (full length or truncated), inclusion of multiple TAA to 
recruit the optimal combination of APC, and the resultant skewing of the T cell 
response to either an IFN-ぐ or IL-17 producing phenotype.  Therefore, in addition to 
generation of neoantigens through sequence mutation, immunological tolerance 
against self-TAA can be broken through manipulation of protein integrity, allowing 
for rational design of better self immunogens for cancer immunotherapy.   
 
 
 
 
